Intermittent Claudication
Clinical Snapshot
Peripheral artery disease (PAD) is atherosclerotic narrowing of the lower-limb arteries. Intermittent claudication (IC) is its classic symptomatic presentation — exertional muscle discomfort, cramping, or fatigue that is reproducibly brought on by a consistent amount of walking and reproducibly relieved by a short period of rest, typically within about 10 minutes.[1] PAD is not always symptomatic in this classic way — it can be entirely asymptomatic, or it can present at the severe end of its spectrum as chronic limb-threatening ischemia or acute limb ischemia (see Recognize the Condition).
The single most important concept in managing IC is that it has 2 distinct, simultaneously pursued goals that are not interchangeable. The primary goal is cardiovascular risk reduction: PAD is not a localized leg problem but a marker of systemic atherosclerosis, and a patient with symptomatic PAD carries a risk of myocardial infarction, stroke, and cardiovascular death comparable to a patient with established coronary artery disease — antiplatelet therapy, high-intensity statin therapy, blood pressure and glycemic control, and smoking cessation address this risk directly and are indicated in essentially every patient regardless of how mild the leg symptoms are. The secondary goal is symptom and functional improvement — increasing pain-free and maximal walking distance and preserving mobility and quality of life — addressed through supervised exercise therapy and, when needed, symptom-directed pharmacotherapy. Treating only the leg symptoms while leaving cardiovascular risk unaddressed is a common and consequential error.[2]
Recognize the Condition
Typical presentation
Exertional discomfort, cramping, tightness, or fatigue in a specific muscle group — most often the calf, but sometimes the thigh or buttock with more proximal (aortoiliac) disease — brought on reproducibly after walking a consistent distance and resolving reproducibly with a short period of standing rest, usually within about 10 minutes. The pain does not require sitting down or a change in posture to resolve, and it recurs at a similar distance each time walking resumes (see Assessment & Diagnosis for how this differs from other causes of exertional leg pain).
Classifying walking-distance severity
Document the walking distance or time to onset of claudication at every assessment — it is both a diagnostic clue and the outcome measure used to track response to treatment:
- Mild: claudication onset after more than 1 city block (roughly 100 m, or about 300 ft).
- Moderate: claudication onset between one-half and 1 city block.
- Severe: claudication onset before one-half of a city block.
The spectrum of PAD presentations
4 clinical presentations of PAD
Asymptomatic PAD
Confirmed by a reduced ankle-brachial index (see Assessment & Diagnosis) without exertional leg symptoms. Still carries the full cardiovascular risk of PAD and still requires the cardiovascular-risk-reduction track of treatment (see Choose Initial Treatment).
Intermittent claudication
The classic, reproducible exertional-pain-relieved-by-rest pattern described above — the subject of this chapter.
Chronic limb-threatening ischemia (CLTI)
The severe end of the chronic PAD spectrum: ischemic rest pain, non-healing ulceration, or gangrene present for more than 2 weeks, caused by objectively confirmed arterial occlusive disease. Requires urgent vascular surgery referral, not escalation of oral therapy (see Red Flags & Refer).
Acute limb ischemia (ALI)
A sudden drop in limb perfusion — a true vascular emergency, not a variant of chronic claudication. Presents with some or all of the classic "6 Ps": pain, pallor, pulselessness, paresthesia, paralysis, and poikilothermia (a cold limb). Requires immediate emergency referral (see Red Flags & Refer).
Staging systems
Two staging systems are used interchangeably in vascular practice and in referral communication — know both:
| Fontaine stage | Rutherford category | Clinical presentation |
|---|---|---|
| I | 0 | Asymptomatic |
| IIa | 1 | Mild claudication |
| IIa/IIb | 2 | Moderate claudication |
| IIb | 3 | Severe claudication |
| III | 4 | Ischemic rest pain |
| IV | 5 | Minor tissue loss (small ulcer, focal gangrene) |
| IV | 6 | Major tissue loss (extends above the metatarsal level) |
Fontaine III/IV and Rutherford 4-6 together define chronic limb-threatening ischemia.[2]
Risk Factors
Modifiable
- Tobacco use, active or secondhand — the single strongest modifiable risk factor for PAD.
- Diabetes mellitus.
- Dyslipidemia.
- Hypertension.
- Physical inactivity.
- Short sleep duration and daytime napping — an emerging, independently associated risk factor.
Nonmodifiable
- Age — risk rises steadily with age.
- Family history of premature cardiovascular disease.
Associated conditions that raise the likelihood PAD is already present
- Known coronary artery disease or prior myocardial infarction.
- Known cerebrovascular disease or prior TIA/stroke.
- Chronic kidney disease.
Red Flags & Refer
Escalate immediately, not through routine pharmacotherapy titration, for any of the following:
- Signs of chronic limb-threatening ischemia (CLTI) — ischemic rest pain, a non-healing ulceration, or gangrene — require urgent vascular surgery referral for consideration of revascularization; these are not managed by adjusting oral medication.
- Signs of acute limb ischemia (ALI) — sudden onset of some or all of the 6 Ps (pain, pallor, pulselessness, paresthesia, paralysis, poikilothermia/a cold limb) — is a true surgical emergency requiring immediate emergency department referral; every hour of delay risks irreversible tissue loss.
- New or worsening chest pain, or new focal neurologic symptoms — treat as a possible acute coronary syndrome or stroke given the shared atherosclerotic risk, not as a routine claudication follow-up visit.
- Cilostazol prescribed to, or continued in, a patient with heart failure of any severity — this is an absolute contraindication, not a relative caution; stop the drug and do not restart it once heart failure of any severity has been diagnosed (see Choose Initial Treatment and Drug Tables).
Assessment & Diagnosis
Differentiating exertional leg pain: 4 common causes
| Feature | Vascular (arterial) claudication | Neurogenic claudication (lumbar spinal stenosis) | Venous claudication | Musculoskeletal pain (e.g. hip/knee osteoarthritis) |
|---|---|---|---|---|
| Location | A specific muscle group distal to the arterial narrowing — calf most often, thigh or buttock with more proximal disease | Poorly localized, often bilateral; may extend from the back or buttock down both legs | The whole leg, described as tight or bursting | The affected joint, worse with specific movements |
| Onset relative to walking | Reproducible at a consistent walking distance | Variable; may be provoked by standing alone, not only by walking | Gradual buildup over the course of walking, not a fixed distance | Present with activity, often also present at rest or with prolonged standing |
| What relieves it | Standing still; resolves within about 10 minutes | Sitting down or bending forward (lumbar flexion) — standing still alone often does not help, and relief is slower | Leg elevation; slower relief than vascular claudication | Rest and position change; often slower and less complete relief |
| Effect of direction of travel | Worse going uphill or at a faster pace | Often worse going downhill (spinal extension) than uphill (spinal flexion) — the reverse of vascular claudication | Not direction-dependent | Variable, joint-dependent |
| Associated findings | Diminished or absent pulses, bruits, hair loss, dependent rubor, low ankle-brachial index | Normal pulses and normal ankle-brachial index; may have numbness, weakness, or a positive lumbar extension maneuver | Normal pulses; signs of chronic venous insufficiency — edema, varicosities, skin pigmentation change, possible prior DVT history | Normal pulses; joint-line tenderness, reduced range of motion, effusion |
History
- Cardiovascular risk factors and associated conditions: angina or prior MI, diabetes mellitus, dyslipidemia, hypertension, smoking, prior TIA or stroke.
- Walking distance or time to claudication onset, classified as mild/moderate/severe (see Recognize the Condition) — both diagnostic and the baseline against which treatment response is measured.
- Duration of symptoms — collateral circulation typically takes 6-12 months to develop after claudication onset, directly relevant to counselling a patient on how long exercise therapy needs to run before being judged ineffective (see Non-Pharmacologic Treatment).
- Any rest pain, non-healing wound, or colour change in the foot or toes — these suggest progression toward chronic limb-threatening ischemia (see Red Flags & Refer).
Physical examination
- Signs of hypertension, dyslipidemia, diabetes, or atherosclerosis elsewhere — an abdominal aortic aneurysm, carotid or femoral bruits, or signs of heart failure.
- Peripheral pulses — femoral, popliteal, posterior tibial, and dorsalis pedis. A diminished or absent pulse suggests arterial obstruction; conversely, normal pulses and the absence of a bruit make significant obstruction less likely.
- Signs of acute arterial occlusion — sudden, continuous pain; a pale, cool, or mottled limb; and swollen, stiff, tender muscle — is a red flag requiring emergency referral, not an outpatient work-up (see Red Flags & Refer).
- Signs of severe chronic obstruction — rest pain, dependent rubor, cyanosis, muscle atrophy, or trophic ulcers — suggest chronic limb-threatening ischemia (see Red Flags & Refer).
Laboratory testing
- Fasting glucose (or HbA1c), serum creatinine, and a fasting lipid profile.
- Hemoglobin, hematocrit, and platelet count — anemia can worsen claudication symptoms independent of arterial disease.
- Elevated inflammatory markers (e.g. C-reactive protein) or D-dimer are associated with higher short-term cardiovascular and all-cause mortality risk and support a more intensive risk-reduction approach, though they are not required to make the diagnosis.
Ankle-brachial index — the primary diagnostic test
The ankle-brachial index (ABI) is the ratio of the higher systolic pressure at the ankle (dorsalis pedis or posterior tibial artery) to the higher systolic pressure in the arm (brachial artery), measured with a blood pressure cuff and a handheld Doppler device.[2]
| ABI | Interpretation |
|---|---|
| 1.00-1.40 | Normal |
| 0.91-0.99 | Borderline |
| 0.90 or lower | Abnormal — diagnostic of PAD |
| Over 1.40 | Noncompressible — arterial calcification is preventing full compression; the result cannot be interpreted, and a toe-brachial index is needed instead |
Why there is no live calculator for the ABI on this page: the interactive calculator tool on this platform is built specifically for point-sum checkbox scores, where each present criterion adds a fixed number of points — the way the TIMI score works elsewhere on this platform. The ABI is not that kind of score: it is a single division of 2 independently measured systolic pressures (ankle pressure divided by arm pressure), not a sum of present/absent criteria, so it does not fit the checkbox-based tool this platform supports. The table above is for interpreting an ABI result you already have from a Doppler measurement, not for calculating one — there is no substitute for an actual measured ankle and arm pressure.
Further testing
- Toe-brachial index (TBI): use when the ABI is noncompressible (over 1.40) — common in diabetes and chronic kidney disease, where arterial calcification prevents the cuff from compressing the vessel — since digital arteries stay compressible even when the tibial arteries do not.[3]
- Exercise (post-exercise) ABI: when the resting ABI is normal (1.00-1.40) but the history strongly suggests claudication, a treadmill test with ABI measured immediately after exercise can unmask a significant pressure drop that confirms the diagnosis.
- 6-minute walk test: a simple, reproducible functional measure of walking capacity, useful both for diagnosis in equivocal cases and for tracking response to exercise therapy over time.[3]
- Duplex ultrasound, CT angiography, or MR angiography: reserved for patients being considered for revascularization — not needed to diagnose or medically manage claudication.
- Invasive angiography: reserved for patients with signs of severe limb ischemia (rest pain, muscle atrophy, cyanosis, non-healing ischemic ulcers, or gangrene) being worked up for possible angioplasty or surgical revascularization.
When testing is not indicated
Advanced imaging (CT angiography, MR angiography, or invasive angiography) is not indicated simply to confirm a diagnosis of claudication that is already clear from history, exam, and ABI — reserve it for patients in whom revascularization is genuinely being considered, or those with signs of severe or critical limb ischemia.
Treatment Targets
- Reduce the risk of myocardial infarction, stroke, and cardiovascular death — the primary treatment goal in PAD, addressed by cardiovascular risk-reduction therapy (see below).
- Reduce major adverse limb events — progression to chronic limb-threatening ischemia, need for revascularization, or amputation.
- Achieve the statin, blood pressure, and glycemic targets defined in the Dyslipidemias, Hypertension, and Diabetes Mellitus chapters.
- Achieve complete tobacco cessation.
- Increase pain-free and maximal walking distance and time to claudication onset.
- Increase capacity for regular dynamic leg exercise.
- Improve mobility and quality of life, and reduce functional decline.
The 2 treatment tracks in intermittent claudication
Cardiovascular risk reduction (primary goal)
High-intensity statin therapy regardless of baseline LDL, antiplatelet therapy (single agent, or dual pathway inhibition in selected higher-risk patients), blood pressure and glycemic control, and smoking cessation. Indicated in essentially every patient with PAD, symptomatic or not — see Dyslipidemias, Hypertension, and Diabetes Mellitus for the complete dosing frameworks these draw on.
Symptom-directed / functional treatment (secondary goal)
Supervised exercise therapy, first and most effective; cilostazol as the primary symptom-directed drug when exercise alone is insufficient; pentoxifylline as a distant, less-effective alternative. None of these interventions substitute for cardiovascular risk-reduction therapy — they run alongside it, never instead of it.
Choose Initial Treatment
Step 1 — cardiovascular risk reduction (every patient with PAD)
Statin, every patient start a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) regardless of baseline LDL — symptomatic PAD is treated as a statin-indicated, high-risk condition on its own, the same way established coronary disease is; see Dyslipidemias for the complete statin selection, monitoring, and add-on-therapy framework.[1]
Single antiplatelet therapy, default ASA 81 mg daily or clopidogrel 75 mg daily — either is an acceptable default for most patients with symptomatic PAD.
Dual pathway inhibition — selected higher ischemic-risk patients at low bleeding risk rivaroxaban 2.5 mg twice daily added to ASA 81 mg daily reduces major adverse cardiovascular and limb events compared with ASA alone, and is a reasonable choice for a patient with higher-risk features — recent lower-extremity revascularization, polyvascular disease, diabetes, or chronic kidney disease — who does not have an elevated bleeding risk.[2][4]
Avoid routine long-term dual antiplatelet therapy (ASA plus clopidogrel) for claudication alone outside a defined, time-limited period after a specific revascularization procedure — it increases bleeding without a clear long-term benefit over single antiplatelet therapy or dual pathway inhibition in this population.
Step 2 — blood pressure, glycemic control, and smoking cessation
Blood pressure treat to the same targets as any patient at high cardiovascular risk (see Hypertension) — an ACE inhibitor or ARB is a reasonable first choice given added cardiovascular benefit in atherosclerotic disease. Beta-blockers are safe in PAD when otherwise indicated (hypertension, prior MI, arrhythmia) — they do not worsen claudication or reduce walking capacity, despite outdated teaching to the contrary; reserve added caution for severe PAD with critical limb ischemia or an ABI under 0.4.
Diabetes optimize glycemic control to the individualized target in Diabetes Mellitus; in a patient with type 2 diabetes and PAD specifically, an SGLT2 inhibitor is a preferred glucose-lowering choice given its independent benefit for major adverse cardiovascular and limb events — see Diabetes Mellitus and Diabetes Mellitus - Chronic Complications for dosing and selection.
Smoking cessation address at every visit with combined behavioural support and pharmacotherapy — see Tobacco Use Disorder for the complete cessation framework; this is one of the highest-yield interventions available for a patient with PAD and should never be deferred while other therapy is optimized.
Step 3 — symptom-directed treatment
1st line supervised exercise therapy, offered to essentially every patient with claudication at the time of diagnosis, alongside — not instead of — the cardiovascular risk-reduction measures above (see Non-Pharmacologic Treatment for the full program specification).
2nd line — use when claudication remains functionally limiting despite an adequate trial of supervised exercise, or exercise therapy is not accessible cilostazol 100 mg PO twice daily, taken at least 30 minutes before or 2 hours after breakfast and dinner. Continue for a full 12-week trial at an adequate dose before judging benefit.
Never use cilostazol in a patient with heart failure of any severity — this is an absolute contraindication, not a relative caution; confirm the absence of any heart failure history before the first prescription and at every subsequent refill (see Drug Tables).
Special situation — cilostazol contraindicated, not tolerated, or not accessible pentoxifylline 400 mg PO 2-3 times daily is a distant alternative; current guideline evidence has moved away from recommending it given inconsistent, marginal benefit, but it remains an option in Canadian practice, where cilostazol currently has no Health Canada-authorized product. Set expectations accordingly — meaningful improvement in walking distance is far less consistent than with cilostazol or exercise.[5]
Step 4 — critical limb ischemia and acute limb ischemia
Any sign of chronic limb-threatening ischemia or acute limb ischemia (see Red Flags & Refer) is a referral decision, not a pharmacotherapy-escalation decision — refer urgently to vascular surgery rather than adjusting oral drug therapy.
Non-Pharmacologic Treatment
Supervised exercise therapy — the single most effective symptom-directed intervention
Supervised exercise therapy (SET) is a structured, supervised walking program delivered in a hospital or outpatient facility under the direction of a physician or advanced-practice provider, typically implemented day-to-day by a clinical exercise physiologist or nurse. It produces a larger, more consistent improvement in walking distance than any single drug used for claudication, and it should be offered at the time of diagnosis — not reserved as a last resort after drug therapy fails.[6]
- Format: interval (walk-rest-walk) training — walk to moderate-to-severe claudication pain, then rest until the pain resolves, and repeat for the full session.
- Session length: 30-45 minutes of accumulated walking time per session.
- Frequency: at least 3 times per week.
- Minimum duration: 12 weeks; benefit continues to accrue with a longer program.
Ideally, a 3-month period of supervised therapy is followed by transition to a home- or community-based walking program to maintain the gain. Where a hospital-based supervised program is not accessible, a structured home- or community-based program — walking to near-maximal claudication pain, 3 or more times weekly — is a reasonable alternative, though it produces a smaller average benefit than a truly supervised program.[6] Smartphone-based tracking and other adherence-support technology are emerging tools to help sustain a home program.
Set expectations on timing
Tell the patient explicitly, when exercise therapy is started, that dynamic leg exercise sustained for 6-12 months allows collateral circulation to develop around the arterial narrowing, and that continuing regular exercise for 24-36 months slows longer-term functional decline — patients who are not told this timeline often stop adhering before a real effect has had time to appear.
Foot and skin care
- Daily foot inspection, particularly in a patient who also has diabetes or reduced sensation, since early ischemic or neuropathic changes are easy to miss without a deliberate check.
- Well-fitting, protective footwear, and prompt attention to any new wound, blister, or colour change rather than waiting for it to resolve on its own.
- Avoid activities and footwear likely to cause minor trauma — even a minor injury can progress to a non-healing ulcer in significant PAD.
Non-drug management of contributing conditions
Address diabetes, hypertension, dyslipidemia, and obesity with the non-pharmacologic measures described in their own chapters (Diabetes Mellitus, Hypertension, Dyslipidemias, Obesity) — these run in parallel with, not instead of, PAD-specific management.
Revascularization — a procedural option, not a default early step
Revascularization (angioplasty or surgical bypass) does not by itself alter long-term limb outcomes for claudication and does not reliably provide a durable functional or quality-of-life advantage over optimal medical therapy and supervised exercise for most patients with claudication alone.[1] Reserve it for patients with lifestyle-limiting symptoms despite an adequate trial of supervised exercise and optimized medical therapy, or for chronic limb-threatening/acute limb ischemia, rather than offering it as an early or default option for claudication (see Treatment Failure & Next Step).
Special Populations
Pregnancy
Symptomatic PAD is uncommon in patients of reproductive age, since it reflects long-standing atherosclerosis, but the same principles apply if it occurs. Contraindicated in pregnancy statins — see Dyslipidemias. Cilostazol and pentoxifylline are not recommended in pregnancy given insufficient safety data and an animal-study signal; avoid unless the potential benefit clearly outweighs the risk, in consultation with obstetric and vascular specialists. Low-dose ASA at the doses used for PAD is generally considered compatible with pregnancy, but confirm the indication is still needed. ACE inhibitors and ARBs are contraindicated in pregnancy — see Hypertension.
Breastfeeding
Statins are not recommended during breastfeeding — see Dyslipidemias. Cilostazol has been detected in animal milk; discontinue breastfeeding or discontinue the drug. Pentoxifylline and its breakdown products pass into human breast milk; weigh how important the drug is to the mother against stopping breastfeeding or stopping the medication. Low-dose ASA is generally considered compatible with breastfeeding.
Older adults
PAD becomes more common and more severe with age. Older adults are also more likely to have unrecognized heart failure or reduced cardiac reserve — confirm the absence of heart failure explicitly before starting cilostazol, and reconfirm at every refill rather than assuming a stable history. Bleeding risk from any antiplatelet or dual pathway inhibition regimen also rises with age — weigh this explicitly before adding rivaroxaban to ASA in an older patient.
Diabetes
Diabetic peripheral neuropathy can blunt or mask the pain of ischemia, so a patient with diabetes may present later, with a more advanced ulcer or with painless tissue loss rather than classic claudication — keep a lower threshold for foot examination and ABI testing in this population. Arterial calcification frequently makes the ABI falsely elevated (noncompressible, over 1.40) in diabetes — use a toe-brachial index instead when this occurs (see Assessment & Diagnosis). An SGLT2 inhibitor is a preferred glucose-lowering choice in a patient with type 2 diabetes and PAD given its independent cardiovascular and limb benefit — see Diabetes Mellitus and Diabetes Mellitus - Chronic Complications for dosing.
Renal impairment
Avoid rivaroxaban-based dual pathway inhibition in significant renal impairment — confirm current creatinine clearance against the product-specific threshold before starting or continuing it. No dose adjustment is required for cilostazol in mild-to-moderate renal impairment; it has not been studied in severe renal impairment. Pentoxifylline requires a reduced dose in severe renal impairment (creatinine clearance under 30 mL/min) — see Drug Tables.
Monitoring & Follow-Up
- Reassess walking distance/time to claudication onset at each follow-up, using the same method as at baseline (patient-reported distance, a standardized walking-impairment questionnaire, or a 6-minute walk test) — the primary way to judge whether symptom-directed therapy is working.
- Repeat the ABI if the clinical picture changes, or to document a new baseline after a significant change in therapy or after revascularization.
- Follow the lipid-panel, blood-pressure, and glycemic monitoring schedules in Dyslipidemias, Hypertension, and Diabetes Mellitus.
- Reassess tobacco-use status and offer cessation support at every visit until the patient has fully quit.
- Inspect the feet at every visit in a patient with diabetes or any sign of reduced sensation, and ask specifically about any new wound.
- At every cilostazol prescription or refill, ask specifically about new or worsening shortness of breath, swelling, or weight gain, and confirm there is still no diagnosis of heart failure.
- Reassess cilostazol or pentoxifylline benefit at 12 weeks; discontinue if there has been no meaningful improvement in walking distance at an adequate dose and duration.
- Monitor for bleeding at every visit in a patient on dual pathway inhibition or any antiplatelet/anticoagulant combination.
Common Errors to Avoid
- Focusing on leg symptoms alone and neglecting cardiovascular risk reduction — the primary treatment goal in PAD is preventing MI, stroke, and cardiovascular death, not just improving walking distance.
- Prescribing or continuing cilostazol without explicitly asking about heart failure at every new prescription and every refill — this is an absolute, not relative, contraindication.
- Reaching for a drug before offering supervised exercise therapy, which is the single most effective symptom-directed intervention and is often underutilized relative to its effectiveness.
- Treating pentoxifylline as if it remains a guideline-preferred option — current evidence has moved decisively away from it, and it is now a distant, honestly-framed alternative rather than routine therapy.
- Avoiding beta-blockers in PAD out of outdated concern that they worsen claudication — current evidence shows they do not meaningfully impair walking capacity and are appropriate when otherwise indicated.
- Trusting a normal or high ankle-brachial index in a patient with diabetes or chronic kidney disease without considering that arterial calcification can make the result falsely elevated (noncompressible) — a toe-brachial index is needed in that situation.
- Escalating oral pharmacotherapy in a patient with new rest pain, a non-healing ulcer, or signs of acute limb ischemia instead of referring urgently for vascular assessment.
- Missing the opportunity to start an SGLT2 inhibitor in a patient who has both type 2 diabetes and PAD, given its independent benefit for major adverse limb events.
- Setting no explicit timeline expectation for exercise therapy — patients who are not told that collateral circulation takes 6-12 months to develop often stop adhering before a real effect has appeared.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.
Antiplatelet Agents
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| ASA | Usual dose: 81 mg PO daily Alternative range: 80-325 mg PO daily | GI upset, GI bleeding, rare bronchospasm | Increased bleeding with anticoagulants and other antiplatelet agents | Acceptable single-antiplatelet default for most patients with symptomatic PAD. |
| Clopidogrel | Usual dose: 75 mg PO daily | Bleeding, rash, diarrhea | Proton pump inhibitor use may reduce efficacy | Equally acceptable single-antiplatelet default; useful when ASA is not tolerated. |
| Rivaroxaban (dual pathway inhibition, combined with ASA) | Dual pathway inhibition (with ASA): rivaroxaban 2.5 mg PO BID + ASA 81 mg PO daily | Bleeding | Avoid combining with strong dual inhibitors of CYP3A4 and P-glycoprotein (e.g. itraconazole, ritonavir); avoid combining with strong dual inducers of both (e.g. phenytoin, rifampin) where possible | Reserve for higher ischemic-risk patients (recent lower-extremity revascularization, polyvascular disease, diabetes, or chronic kidney disease) who are not at increased bleeding risk. Avoid in significant renal impairment — confirm current creatinine clearance against the product-specific threshold. |
Lipid-Lowering Therapy (summary — see Dyslipidemias for the complete class table)
Every patient with symptomatic PAD is treated at high intensity, regardless of baseline LDL — the same threshold used for established coronary artery disease.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Atorvastatin | High-intensity (required in symptomatic PAD): 40-80 mg PO daily | Myalgia, transaminase elevation | Avoid strong CYP3A4 inhibitors (amiodarone, azole antifungals, macrolides, protease inhibitors, verapamil/diltiazem) | See Dyslipidemias for the complete statin selection, monitoring, and add-on-therapy framework. |
| Rosuvastatin | High-intensity (required in symptomatic PAD): 20-40 mg PO daily | Myalgia, transaminase elevation | Avoid strong CYP2C9 inhibitors; increased levels with cyclosporine | See Dyslipidemias; start at 5 mg/day instead of 10 mg/day in select ancestry groups per that chapter. |
Symptom-Directed Pharmacotherapy
Neither agent below reduces cardiovascular events or mortality — both are used only to improve walking distance, alongside (never instead of) the cardiovascular risk-reduction therapy above. Naftidrofuryl, used for this purpose in some European countries, is not available in Canada and is not discussed further here.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cilostazol | Usual dose: 100 mg PO BID, at least 30 min before or 2 h after breakfast and dinner With a CYP3A4 or CYP2C19 inhibitor: 50 mg PO BID | Headache (most common, and the most common reason for stopping), diarrhea, palpitations, dizziness | Reduce the dose with a CYP3A4 inhibitor (diltiazem, erythromycin, clarithromycin, itraconazole, ketoconazole) or a CYP2C19 inhibitor (omeprazole, fluconazole, ticlopidine); avoid grapefruit juice | Absolutely contraindicated in heart failure of any severity — confirm the absence of heart failure before every new prescription and at every refill. Continue for a full 12-week trial at an adequate dose before judging benefit; discontinue if there is no improvement after 3 months. Currently has no Health Canada-authorized product or drug identification number in Canada. |
| Pentoxifylline | Usual dose: 400 mg PO 2-3 times daily, after meals Severe renal impairment (creatinine clearance under 30 mL/min): 400 mg PO once daily | Nausea, dyspepsia, dizziness, headache, flushing | May increase theophylline levels; enhances the effect of antihypertensive agents; increased bleeding risk with anticoagulants or other antiplatelet agents | Weaker and less consistent evidence for improving walking distance than cilostazol; current guideline evidence has moved away from recommending it. It remains available in Canada with Health Canada authorization, unlike cilostazol, so it stays an option when cilostazol cannot be used or accessed. |
Evidence note: Dual pathway inhibition dosing is cross-checked against the current ACC/AHA lower-extremity PAD guideline.[2] Cilostazol's dosing, heart-failure contraindication, and Canadian availability status are cross-checked against the current Canadian Cardiovascular Society PAD guideline and the independent Health Canada regulatory record.[1]
References
- Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease — Canadian Journal of Cardiology (Abramson BL, Al-Omran M, Anand SS, et al.). Can J Cardiol 2022;38(5):560-587
- 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease — Journal of the American College of Cardiology (Gornik HL, Aronow HD, Goodney PP, et al.). J Am Coll Cardiol 2024;83(24):2497-2604
- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication — European Journal of Vascular and Endovascular Surgery (Nordanstig J, Behrendt CA, Baumgartner I, et al.). Eur J Vasc Endovasc Surg 2024;67(1):9-96
- Rivaroxaban in Peripheral Artery Disease after Revascularization — New England Journal of Medicine (Bonaca MP, Bauersachs RM, Anand SS, et al.). N Engl J Med 2020;382(21):1994-2004
- Regulatory Decision Summary — Cilostazol (Zetpliya) — Health Canada, Drug and Health Products Portal. Health Canada Regulatory Decision Summary, submission discontinued 2021
- Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association — Circulation, American Heart Association (Treat-Jacobson D, McDermott MM, Bronas UG, et al.). Circulation 2019;139(4):e10-e33
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.